Asset Details
Do you wish to reserve the book?
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
Do you wish to request the book?
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
2020
Overview
The Hellenic Sepsis Study Group (HSSG, www.sepsis.gr) is collecting clinical information and serum samples within the first 24 h of admission from patients with infections and at least two signs of the systemic inflammatory response syndrome. Since March 1, 2020, 57 patients with community-acquired pneumonia and molecular documentation of SARS-CoV-2 in respiratory secretions were enrolled. Patients were followed up daily for 14 days; the development of SRF defined as PO2/FiO2 ratio less than 150 requiring mechanical ventilation (MV) or continuous positive airway pressure treatment (CPAP) was recorded. suPAR was measured by an enzyme immunoassay in duplicate (suPARnostic™, ViroGates, Lyngby, Denmark); the lower detection limit was 1.1 ng/ml. Measured levels were compared to those collected from 15 patients with COVID-19 from the emergency department (ED) of Rush University Medical Center.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Clinical Laboratory Techniques
/ Coronavirus Infections - diagnosis
/ COVID-19
/ Female
/ Humans
/ Male
/ Medicine
/ Pneumonia, Viral - diagnosis
/ Receptors, Urokinase Plasminogen Activator - blood
/ Respiratory Insufficiency - diagnosis
/ Respiratory Insufficiency - virology
/ Sepsis
/ Severe acute respiratory syndrome coronavirus 2
/ suPAR
